PRESS RELEASE:
Nanexa & Neoventa Medical
Nanomaterial sensors to measure
lactate during labour and delivery
Nanexa & Neoventa Medical
Nanomaterial sensors to measure
lactate during labour and delivery
New Nanotechnology opens up new possibilities
in perinatal care that may significantly improve
outcomes during childbirth.
Monday June 14, 2010
Researchers at the Ångström Laboratory in Uppsala, Sweden have discovered a new
method to manufacture nanomaterial sensors so that it becomes possible to for example measure different components of body liquids, i.e. blood or amniotic fluid.
Nanexa AB, the company that now owns this technology, has recently signed an exclusive
agreement with Neoventa Medical AB to develop this very promising technology with in the
perinatal care area. In the first application Neoventa and Nanexa will develop a sensor that
measures lactate during labour and delivery. Lactate is an indicator for oxygen depletion of
the fetus.
Being able to measure the lactate level in this way is a huge advantage compared to how this
is done today says Professor Magnus Westgren at the Karolinska University Hospital. “Not
only do we make the procedure considerably easier for the healthcare personnel but also
possible to measure the lactate level of the fetus earlier than what is possible today.”
With the combination of lactate and our ST Analysis the information of how well the baby
is doing during labour will improve one step further says Jan Stålemark, CEO Neoventa
Medical. “The advantage is also that lactate is an already recognized parameter with scientific
evidence. With this new technology we believe that we can help doctors and nurses to make
better informed decisions improving the outcome. Although poor outcome is infrequent the
consequences are fatal for the parents, their family, friends and of course the baby. In addition,
the cost for a poor outcome is enormous today and continues to increase. Both medical legal
claims and a potential life long handicap adds up to astronomic amounts. We know already
today that ST Analysis is cost effective alone according to a publication in the BJOG 2008.
With the combination of lactate we believe that we can improve outcome further and make the
application even more cost effective.“
The sensor technology is unique and has the advantage that it is not necessary to draw a blood
sample from the patient since the sensor measures the lactate level of the baby directly at the
tip of the fetal scalp electrode.
Professor Jan-Otto Carlsson at Nanexa says that the sensor technology can basically detect
any components with good accuracy in both liquid and gas samples. “The application takes
advantage of the Nobel priced innovation of Raman Spectroscopy and Nanexa’s unique sensor
tip making the sampling specific for certain components. Since it is a spectroscopic technique
many species can be measured simultaneously.”
Christian Östberg, CEO at Nanexa comments “Our development collaboration with Neoventa
is outstanding and I am very pleased to announce this agreement for our ultra sensitive
sensor within the field of perinatal monitoring. This agreement is an important step towards
Nanexa becoming a sustainable supplier to the medical device industry. We are convinced that
Neoventa will make the new product a success.”
Press Release issued by Neoventa Medical
in perinatal care that may significantly improve
outcomes during childbirth.
Monday June 14, 2010
Researchers at the Ångström Laboratory in Uppsala, Sweden have discovered a new
method to manufacture nanomaterial sensors so that it becomes possible to for example measure different components of body liquids, i.e. blood or amniotic fluid.
Nanexa AB, the company that now owns this technology, has recently signed an exclusive
agreement with Neoventa Medical AB to develop this very promising technology with in the
perinatal care area. In the first application Neoventa and Nanexa will develop a sensor that
measures lactate during labour and delivery. Lactate is an indicator for oxygen depletion of
the fetus.
Being able to measure the lactate level in this way is a huge advantage compared to how this
is done today says Professor Magnus Westgren at the Karolinska University Hospital. “Not
only do we make the procedure considerably easier for the healthcare personnel but also
possible to measure the lactate level of the fetus earlier than what is possible today.”
With the combination of lactate and our ST Analysis the information of how well the baby
is doing during labour will improve one step further says Jan Stålemark, CEO Neoventa
Medical. “The advantage is also that lactate is an already recognized parameter with scientific
evidence. With this new technology we believe that we can help doctors and nurses to make
better informed decisions improving the outcome. Although poor outcome is infrequent the
consequences are fatal for the parents, their family, friends and of course the baby. In addition,
the cost for a poor outcome is enormous today and continues to increase. Both medical legal
claims and a potential life long handicap adds up to astronomic amounts. We know already
today that ST Analysis is cost effective alone according to a publication in the BJOG 2008.
With the combination of lactate we believe that we can improve outcome further and make the
application even more cost effective.“
The sensor technology is unique and has the advantage that it is not necessary to draw a blood
sample from the patient since the sensor measures the lactate level of the baby directly at the
tip of the fetal scalp electrode.
Professor Jan-
advantage of the Nobel priced innovation of Raman Spectroscopy and Nanexa’s unique sensor
tip making the sampling specific for certain components. Since it is a spectroscopic technique
many species can be measured simultaneously.”
Christian Östberg, CEO at Nanexa comments “Our development collaboration with Neoventa
is outstanding and I am very pleased to announce this agreement for our ultra sensitive
sensor within the field of perinatal monitoring. This agreement is an important step towards
Nanexa becoming a sustainable supplier to the medical device industry. We are convinced that
Neoventa will make the new product a success.”
Press Release issued by Neoventa Medical